Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]
- D. Oh
- , A. R. He
- , S. Qin
- , L. Chen
- , T. Okusaka
- , A. Vogel
- , J. W. Kim
- , T. Suksombooncharoen
- , M. A. Lee
- , M. Kitano
- , H. A. Burris
- , M. Bouattour
- , S. Tanasa
- , R. E. Zaucha
- , A. Avallone
- , J. E. Cundom
- , N. Rokutanda
- , M. Żotkiewicz
- , G. Cohen
- , J. W. Valle
- Seoul National University
- Georgetown University
- Jinling Hospital
- National Cheng Kung University
- National Cancer Center Japan
- Hannover Medical School
- Chiang Mai University
- Wakayama Medical University
- Sarah Cannon Research Institute
- Assistance publique – Hôpitaux de Paris
- Chulalongkorn University
- Medical University of Gdańsk
- IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
- Instituto de Investigaciones Metabólicas
- AstraZeneca
- The Christie NHS Foundation Trust
Research output: Contribution to journal › Comment/debate
2
Scopus
citations